Back to Search
Start Over
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk
- Source :
- Couch, F J, Wang, X S, McGuffog, L, Lee, A, Olswold, C, Kuchenbaecker, K B, Soucy, P, Fredericksen, Z, Barrowdale, D, Dennis, J, Gaudet, M M, Dicks, E, Kosel, M, Healey, S, Sinilnikova, O M, Bacot, F, Vincent, D, Hogervorst, F B L, Peock, S, Stoppa-Lyonnet, D, Jakubowska, A, Radice, P, Schmutzler, R K, Domchek, S M, Piedmonte, M, Singer, C F, Friedman, E, Thomassen, M, Hansen, T V O, Neuhausen, S L, Szabo, C I, Blanco, I, Greene, M H, Karlan, B Y, Garber, J, Phelan, C M, Weitzel, J N, Montagna, M, Olah, E, Andrulis, I L, Godwin, A K, Yannoukakos, D, Goldgar, D E, Caldes, T, Nevanlinna, H, Osorio, A, Terry, M B, Daly, M B, van Rensburg, E J, Hamann, U, Ramus, S J, Toland, A E, Caligo, M A, Olopade, O I, Tung, N, Claes, K, Beattie, M S, Southey, M C, Imyanitov, E N, Tischkowitz, M, Janavicius, R, John, E M, Kwong, A, Diez, O, Balmana, J, Barkardottir, R B, Arun, B K, Rennert, G, Teo, S H, Ganz, P A, Campbell, I, van der Hout, A H, van Deurzen, C H M, Seynaeve, C, Garcia, E B G, van Leeuwen, F E, Meijers-Heijboer, H E J, Gille, J J P, Ausems, M G E M, Blok, M J, Ligtenberg, M J L, Rookus, M A, Devilee, P, Verhoef, S, van Os, T A M, Wijnen, J T, Frost, D, Ellis, S, Fineberg, E, Platte, R, Evans, D G, Izatt, L, Eeles, R A, Adlard, J, Eccles, D M, Cook, J, Brewer, C, Douglas, F & Hodgson, S 2013, ' Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk ', PLoS Genetics, vol. 9, no. 3, e1003212 . https://doi.org/10.1371/journal.pgen.1003212, Plos Genetics, 9, kConFab Investigators 2013, ' Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk ', P L o S Genetics, vol. 9, no. 3, e1003212., pp. 1-21 . https://doi.org/10.1371/journal.pgen.1003212, Plos Genetics, 9(3):1003212. Public Library of Science, Plos Genetics, 9, 3, PLoS Genetics, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, PLoS genetics, 9(3):e1003212. PUBLIC LIBRARY SCIENCE, PLoS Genetics; 9(3), no e1003212 (2013), PLoS Genetics, 9(3), PLoS Genetics, 2013, 9, pp.e1003212. ⟨10.1371/journal.pgen.1003212⟩, Digital.CSIC. Repositorio Institucional del CSIC, PLoS Genetics (print), 9(3). Public Library of Science, Couch, F J, Wang, X, McGuffog, L, Lee, A R, Olswold, C, Kuchenbaecker, K B, Soucy, P, Fredericksen, Z, Barrowdale, D, Dennis, J, Gaudet, M M, Dicks, E, Kosel, M, Healey, S, Sinilnikova, O M, Lee, A, Bacot, F, Vincent, D, Hogervorst, F B L, Peock, S, Stoppa-Lyonnet, D, Jakubowska, A, Radice, P, Schmutzler, R K, Domchek, S M, Piedmonte, M, Singer, C F, Friedman, E, Thomassen, M, Hansen, T V O, Neuhausen, S L, Szabo, C I, Blanco, I, Greene, M H, Karlan, B Y, Garber, J, Phelan, C M, Weitzel, J N, Montagna, M, Olah, E, Andrulis, I L, Godwin, A K, Yannoukakos, D, Goldgar, D E, Caldes, T, Nevanlinna, H, Skytte, A-B, Gerdes, A-M, Moeller, S T, Kruse, T A & kConFab Investigators 2013, ' Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk ', P L o S Genetics, vol. 9, no. 3, pp. e1003212 . https://doi.org/10.1371/journal.pgen.1003212, PLOS GENETICS, PLoS Genetics, Vol 9, Iss 3, p e1003212 (2013), Dipòsit Digital de la UB, Universidad de Barcelona, PLoS Genetics, 9(3):e1003212. Public Library of Science, Recercat. Dipósit de la Recerca de Catalunya, Couch, F J, Wang, X, McGuffog, L, Lee, A R, Olswold, C, Kuchenbaecker, K B, Soucy, P, Fredericksen, Z, Barrowdale, D, Dennis, J, Gaudet, M M, Dicks, E, Kosel, M, Healey, S, Sinilnikova, O M, Lee, A, Bacot, F, Vincent, D, Hogervorst, F B L, Peock, S, Stoppa-Lyonnet, D, Jakubowska, A, Investigators, K, Radice, P, Schmutzler, R K, Domchek, S M, Piedmonte, M, Singer, C F, Friedman, E, Thomassen, M, Hansen, T V O, Neuhausen, S L, Szabo, C I, Blanco, I, Greene, M H, Karlan, B Y, Garber, J, Phelan, C M, Weitzel, J N, Montagna, M, Olah, E, Andrulis, I L, Godwin, A K, Yannoukakos, D, Goldgar, D E, Caldes, T, Nevanlinna, H, Osorio, A, Pedersen, I S, Jensen, U B, SWE-BRCA & Skytte, A-B S 2013, ' Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk ', PLoS genetics, vol. 9, no. 3, pp. e1003212 . https://doi.org/10.1371/journal.pgen.1003212, PLoS Genetics, Public Library of Science, 2013, 9, pp.e1003212. ⟨10.1371/journal.pgen.1003212⟩, PLoS Genetics; Vol 9, PLoS genetics, 9(3). Public Library of Science, Plos Genetics, 9(3). Public Library of Science
- Publication Year :
- 2013
-
Abstract
- This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- CIMBA et al.<br />BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7 × 10(-8), HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2×10(-4)). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%-50% compared to 81%-100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.<br />The study was supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure; Cancer Research UK grants C12292/A11174 and C1287/A10118; the European Commission's Seventh Framework Programme grant agreement 223175 (HEALTH-F2-2009-223175). Breast Cancer Family Registry Studies (BCFR): supported by the National Cancer Institute, National Institutes of Health under RFA # CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Cancer Prevention Institute of California (U01 CA69417), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), and University of Melbourne (U01 CA69638). The Australian BCFR was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the Victorian Breast Cancer Research Consortium. Melissa C. Southey is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. Carriers at FCCC were also identified with support from National Institutes of Health grants P01 CA16094 and R01 CA22435. The New York BCFR was also supported by National Institutes of Health grants P30 CA13696 and P30 ES009089. The Utah BCFR was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH grant UL1 RR025764, and by Award Number P30 CA042014 from the National Cancer Institute. Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC): BFBOCC is partly supported by Lithuania (BFBOCC-LT), Research Council of Lithuania grant LIG-19/2010, and Hereditary Cancer Association (Paveldimo vėžio asociacija).<br />Latvia (BFBOCC-LV) is partly supported by LSC grant 10.0010.08 and in part by a grant from the ESF Nr.2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016.BRCA-gene mutations and breast cancer in South African women (BMBSA): BMBSA was supported by grants from the Cancer Association of South Africa (CANSA) to Elizabeth J. van Rensburg. Beckman Research Institute of the City of Hope (BRICOH): Susan L. Neuhausen was partially supported by the Morris and Horowitz Families Endowed Professorship. BRICOH was supported by NIH R01CA74415 and NIH P30 CA033752. Copenhagen Breast Cancer Study (CBCS): The CBCS study was supported by the NEYE Foundation. Spanish National Cancer Centre (CNIO): This work was partially supported by Spanish Association against Cancer (AECC08), RTICC 06/0020/1060, FISPI08/1120, Mutua Madrileña Foundation (FMMA) and SAF2010-20493. City of Hope Cancer Center (COH): The City of Hope Clinical Cancer Genetics Community Research Network is supported by Award Number RC4A153828 (PI: Jeffrey N. Weitzel) from the National Cancer Institute and the Office of the Director, National Institutes of Health. CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella (CONSIT TEAM): CONSIT TEAM was funded by grants from Fondazione Italiana per la Ricerca sul Cancro (Special Project “Hereditary tumors”), Italian Association for Cancer Research (AIRC, IG 8713), Italian Minitry of Health (Extraordinary National Cancer Program 2006, “Alleanza contro il Cancro” and “Progetto Tumori Femminili), Italian Ministry of Education, University and Research (Prin 2008) Centro di Ascolto Donne Operate al Seno (CAOS) association and by funds from Italian citizens who allocated the 5×1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects ‘5×1000’). German Cancer Research Center (DKFZ): The DKFZ study was supported by the DKFZ. The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON): HEBON is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the NWO grant 91109024, the Pink Ribbon grant 110005, and the BBMRI grant CP46/NWO.<br />Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE): EMBRACE is supported by Cancer Research UK Grants C1287/A10118 and C1287/A11990. D. Gareth Evans and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Rosalind A. Eeles and Elizabeth Bancroft are supported by Cancer Research UK Grant C5047/A8385. Fox Chase Cancer Canter (FCCC): The authors acknowledge support from The University of Kansas Cancer Center and the Kansas Bioscience Authority Eminent Scholar Program. Andrew K. Godwin was funded by 5U01CA113916, R01CA140323, and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC): The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no 109076, Rita K. Schmutzler) and by the Center for Molecular Medicine Cologne (CMMC). Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO): The GEMO study was supported by the Ligue National Contre le Cancer; the Association “Le cancer du sein, parlons-en!” Award and the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program. Gynecologic Oncology Group (GOG): This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office and Tissue Bank (CA 27469), Statistical and Data Center (CA 37517), and GOG's Cancer Prevention and Control Committtee (CA 101165). Drs. Mark H. Greene and Phuong L. Mai were supported by funding from the Intramural Research Program, NCI, NIH. Hospital Clinico San Carlos (HCSC): HCSC was supported by RETICC 06/0020/0021, FIS research grant 09/00859, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitivity, and the European Regional Development Fund (ERDF).<br />Helsinki Breast Cancer Study (HEBCS): The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, the Nordic Cancer Union, and the Sigrid Juselius Foundation. Study of Genetic Mutations in Breast and Ovarian Cancer patients in Hong Kong and Asia (HRBCP): HRBCP is supported by The Hong Kong Hereditary Breast Cancer Family Registry and the Dr. Ellen Li Charitable Foundation, Hong Kong. Molecular Genetic Studies of Breast and Ovarian Cancer in Hungary (HUNBOCS): HUNBOCS was supported by Hungarian Research Grant KTIA-OTKA CK-80745 and the Norwegian EEA Financial Mechanism HU0115/NA/2008-3/ÖP-9. Institut Català d'Oncologia (ICO): The ICO study was supported by the Asociación Española Contra el Cáncer, Spanish Health Research Foundation, Ramón Areces Foundation, Carlos III Health Institute, Catalan Health Institute, and Autonomous Government of Catalonia and contract grant numbers: ISCIIIRETIC RD06/0020/1051, PI09/02483, PI10/01422, PI10/00748, 2009SGR290, and 2009SGR283. International Hereditary Cancer Centre (IHCC): Supported by the Polish Foundation of Science. Katarzyna Jaworska is a fellow of International PhD program, Postgraduate School of Molecular Medicine, Warsaw Medical University. Iceland Landspitali–University Hospital (ILUH): The ILUH group was supported by the Icelandic Association “Walking for Breast Cancer Research” and by the Landspitali University Hospital Research Fund. INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility (INHERIT): INHERIT work was supported by the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program, the Canadian Breast Cancer Research Alliance grant 019511 and the Ministry of Economic Development, Innovation and Export Trade grant PSR-SIIRI-701. Jacques Simard is Chairholder of the Canada Research Chair in Oncogenetics.<br />Istituto Oncologico Veneto (IOVHBOCS): The IOVHBOCS study was supported by Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero della Salute (“Progetto Tumori Femminili” and RFPS 2006-5-341353,ACC2/R6.9”). Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab): kConFab is supported by grants from the National Breast Cancer Foundation and the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; and the Cancer Foundation of Western Australia. Amanda B. Spurdle is an NHMRC Senior Research Fellow. The Clinical Follow Up Study was funded from 2001–2009 by NHMRC and currently by the National Breast Cancer Foundation and Cancer Australia #628333. Mayo Clinic (MAYO): MAYO is supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defence Ovarian Cancer Idea award (W81XWH-10-1-0341) and grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure. McGill University (MCGILL): The McGill Study was supported by Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation, and Export Trade. Memorial Sloan-Kettering Cancer Center (MSKCC): The MSKCC study was supported by Breast Cancer Research Foundation, Niehaus Clinical Cancer Genetics Initiative, Andrew Sabin Family Foundation, and Lymphoma Foundation. Modifier Study of Quantitative Effects on Disease (MODSQUAD): MODSQUAD was supported by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101). Women's College Research Institute, Toronto (NAROD): NAROD was supported by NIH grant: 1R01 CA149429-01. National Cancer Institute (NCI): Drs. Mark H. Greene and Phuong L. Mai were supported by the Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Rockville, MD. National Israeli Cancer Control Center (NICCC): NICCC is supported by Clalit Health Services in Israel. Some of its activities are supported by the Israel Cancer Association and the Breast Cancer Research Foundation (BCRF), NY. N. N. Petrov Institute of Oncology (NNPIO): The NNPIO study has been supported by the Russian Foundation for Basic Research (grants 11-04-00227, 12-04-00928, and 12-04-01490), the Federal Agency for Science and Innovations, Russia (contract 02.740.11.0780), and through a Royal Society International Joint grant (JP090615). The Ohio State University Comprehensive Cancer Center (OSU-CCG): OSUCCG is supported by the Ohio State University Comprehensive Cancer Center.<br />South East Asian Breast Cancer Association Study (SEABASS): SEABASS is supported by the Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation. Sheba Medical Centre (SMC): The SMC study was partially funded through a grant by the Israel Cancer Association and the funding for the Israeli Inherited Breast Cancer Consortium. Swedish Breast Cancer Study (SWE-BRCA): SWE-BRCA collaborators are supported by the Swedish Cancer Society. The University of Chicago Center for Clinical Cancer Genetics and Global Health (UCHICAGO): UCHICAGO is supported by grants from the US National Cancer Institute (NIH/NCI) and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women's Cancer Research Alliance, and the Breast Cancer Research Foundation. University of California Los Angeles (UCLA): The UCLA study was supported by the Jonsson Comprehensive Cancer Center Foundation and the Breast Cancer Research Foundation. University of California San Francisco (UCSF): The UCSF study was supported by the UCSF Cancer Risk Program and the Helen Diller Family Comprehensive Cancer Center. United Kingdom Familial Ovarian Cancer Registries (UKFOCR): UKFOCR was supported by a project grant from CRUK to Paul Pharoah. University of Pennsylvania (UPENN): The UPENN study was supported by the National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855), Breast Cancer Research Foundation, Rooney Family Foundation, Susan G. Komen Foundation for the Cure, and the Macdonald Family Foundation. Victorian Familial Cancer Trials Group (VFCTG): The VFCTG study was supported by the Victorian Cancer Agency, Cancer Australia, and National Breast Cancer Foundation. Women's Cancer Research Initiative (WCRI): The WCRI at the Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN).
- Subjects :
- SELECTION
Oncology
Cancer Research
Medicin och hälsovetenskap
endocrine system diseases
[SDV]Life Sciences [q-bio]
610 Medizin
Càncer d'ovari
SUSCEPTIBILITY ALLELES
MODIFIERS
ComputingMilieux_LEGALASPECTSOFCOMPUTING
Genome-wide association study
QH426-470
Medical and Health Sciences
SUBTYPES
Breast cancer
0302 clinical medicine
Human genetics
3123 Gynaecology and paediatrics
Risk Factors
GENETIC-VARIANTS
Genotype
Naturvetenskap
Malalties hereditàries
INVESTIGATORS
skin and connective tissue diseases
ComputingMilieux_MISCELLANEOUS
Genetics (clinical)
POPULATION
Ovarian Neoplasms
Genetics
Subtypes
ddc:610
0303 health sciences
education.field_of_study
Genètica humana
Susceptibility alleles
BRCA1 Protein
COMMON VARIANTS
Breast Cancer Epidemiology
Middle Aged
Prognosis
BRCA2 Protein
3. Good health
030220 oncology & carcinogenesis
Female
Natural Sciences
Genetic diseases
Heterozygote
medicine.medical_specialty
Znf365
education
3122 Cancers
Population
Breast Neoplasms
Single-nucleotide polymorphism
Biology
Polymorphism, Single Nucleotide
Càncer de mama
03 medical and health sciences
SDG 3 - Good Health and Well-being
Ovarian cancer
Translational research [ONCOL 3]
Internal medicine
medicine
Humans
Genetic Predisposition to Disease
Genetics and epigenetic pathways of disease Translational research [NCMLS 6]
Molecular Biology
Selection
ddc:614
Ecology, Evolution, Behavior and Systematics
030304 developmental biology
Hereditary cancer and cancer-related syndromes [ONCOL 1]
Common variants
CONSORTIUM
Modifiers
Biology and Life Sciences
BRCA1
medicine.disease
R1
Genetic-variants
Cancer and Oncology
Mutation
Investigators
3111 Biomedicine
ZNF365
Consortium
Genome-Wide Association Study
Subjects
Details
- ISSN :
- 15537404 and 15537390
- Database :
- OpenAIRE
- Journal :
- Couch, F J, Wang, X S, McGuffog, L, Lee, A, Olswold, C, Kuchenbaecker, K B, Soucy, P, Fredericksen, Z, Barrowdale, D, Dennis, J, Gaudet, M M, Dicks, E, Kosel, M, Healey, S, Sinilnikova, O M, Bacot, F, Vincent, D, Hogervorst, F B L, Peock, S, Stoppa-Lyonnet, D, Jakubowska, A, Radice, P, Schmutzler, R K, Domchek, S M, Piedmonte, M, Singer, C F, Friedman, E, Thomassen, M, Hansen, T V O, Neuhausen, S L, Szabo, C I, Blanco, I, Greene, M H, Karlan, B Y, Garber, J, Phelan, C M, Weitzel, J N, Montagna, M, Olah, E, Andrulis, I L, Godwin, A K, Yannoukakos, D, Goldgar, D E, Caldes, T, Nevanlinna, H, Osorio, A, Terry, M B, Daly, M B, van Rensburg, E J, Hamann, U, Ramus, S J, Toland, A E, Caligo, M A, Olopade, O I, Tung, N, Claes, K, Beattie, M S, Southey, M C, Imyanitov, E N, Tischkowitz, M, Janavicius, R, John, E M, Kwong, A, Diez, O, Balmana, J, Barkardottir, R B, Arun, B K, Rennert, G, Teo, S H, Ganz, P A, Campbell, I, van der Hout, A H, van Deurzen, C H M, Seynaeve, C, Garcia, E B G, van Leeuwen, F E, Meijers-Heijboer, H E J, Gille, J J P, Ausems, M G E M, Blok, M J, Ligtenberg, M J L, Rookus, M A, Devilee, P, Verhoef, S, van Os, T A M, Wijnen, J T, Frost, D, Ellis, S, Fineberg, E, Platte, R, Evans, D G, Izatt, L, Eeles, R A, Adlard, J, Eccles, D M, Cook, J, Brewer, C, Douglas, F & Hodgson, S 2013, ' Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk ', PLoS Genetics, vol. 9, no. 3, e1003212 . https://doi.org/10.1371/journal.pgen.1003212, Plos Genetics, 9, kConFab Investigators 2013, ' Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk ', P L o S Genetics, vol. 9, no. 3, e1003212., pp. 1-21 . https://doi.org/10.1371/journal.pgen.1003212, Plos Genetics, 9(3):1003212. Public Library of Science, Plos Genetics, 9, 3, PLoS Genetics, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, PLoS genetics, 9(3):e1003212. PUBLIC LIBRARY SCIENCE, PLoS Genetics; 9(3), no e1003212 (2013), PLoS Genetics, 9(3), PLoS Genetics, 2013, 9, pp.e1003212. ⟨10.1371/journal.pgen.1003212⟩, Digital.CSIC. Repositorio Institucional del CSIC, PLoS Genetics (print), 9(3). Public Library of Science, Couch, F J, Wang, X, McGuffog, L, Lee, A R, Olswold, C, Kuchenbaecker, K B, Soucy, P, Fredericksen, Z, Barrowdale, D, Dennis, J, Gaudet, M M, Dicks, E, Kosel, M, Healey, S, Sinilnikova, O M, Lee, A, Bacot, F, Vincent, D, Hogervorst, F B L, Peock, S, Stoppa-Lyonnet, D, Jakubowska, A, Radice, P, Schmutzler, R K, Domchek, S M, Piedmonte, M, Singer, C F, Friedman, E, Thomassen, M, Hansen, T V O, Neuhausen, S L, Szabo, C I, Blanco, I, Greene, M H, Karlan, B Y, Garber, J, Phelan, C M, Weitzel, J N, Montagna, M, Olah, E, Andrulis, I L, Godwin, A K, Yannoukakos, D, Goldgar, D E, Caldes, T, Nevanlinna, H, Skytte, A-B, Gerdes, A-M, Moeller, S T, Kruse, T A & kConFab Investigators 2013, ' Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk ', P L o S Genetics, vol. 9, no. 3, pp. e1003212 . https://doi.org/10.1371/journal.pgen.1003212, PLOS GENETICS, PLoS Genetics, Vol 9, Iss 3, p e1003212 (2013), Dipòsit Digital de la UB, Universidad de Barcelona, PLoS Genetics, 9(3):e1003212. Public Library of Science, Recercat. Dipósit de la Recerca de Catalunya, Couch, F J, Wang, X, McGuffog, L, Lee, A R, Olswold, C, Kuchenbaecker, K B, Soucy, P, Fredericksen, Z, Barrowdale, D, Dennis, J, Gaudet, M M, Dicks, E, Kosel, M, Healey, S, Sinilnikova, O M, Lee, A, Bacot, F, Vincent, D, Hogervorst, F B L, Peock, S, Stoppa-Lyonnet, D, Jakubowska, A, Investigators, K, Radice, P, Schmutzler, R K, Domchek, S M, Piedmonte, M, Singer, C F, Friedman, E, Thomassen, M, Hansen, T V O, Neuhausen, S L, Szabo, C I, Blanco, I, Greene, M H, Karlan, B Y, Garber, J, Phelan, C M, Weitzel, J N, Montagna, M, Olah, E, Andrulis, I L, Godwin, A K, Yannoukakos, D, Goldgar, D E, Caldes, T, Nevanlinna, H, Osorio, A, Pedersen, I S, Jensen, U B, SWE-BRCA & Skytte, A-B S 2013, ' Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk ', PLoS genetics, vol. 9, no. 3, pp. e1003212 . https://doi.org/10.1371/journal.pgen.1003212, PLoS Genetics, Public Library of Science, 2013, 9, pp.e1003212. ⟨10.1371/journal.pgen.1003212⟩, PLoS Genetics; Vol 9, PLoS genetics, 9(3). Public Library of Science, Plos Genetics, 9(3). Public Library of Science
- Accession number :
- edsair.doi.dedup.....977d68472191e441a9af93425ef49847
- Full Text :
- https://doi.org/10.1371/journal.pgen.1003212